The Case for Vancomycin as the Preferred Drug for Treatment of Clostridium difficile Infection
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Antibiotic-associated diarrhea became a well-recognized complication of antibiotic use shortly after the introduction of these agents in the early 1950s. Staphylococcus aureus was the presumed pathogen, pseudomembraneous enterocolitis was the characteristic pathologic lesion, and oral vancomycin became the standard method of treatment [1–4]. In 1974, Tedesco et al. [4] published the seminal report on “clindamycin colitis,” showing a 10% rate of pseudomembraneous colitis associated with clindamycin use, but a notable observation in the study was that S. aureus, the presumed etiologic agent of this disease, could not be detected, despite the ease of growing it on selective media. This prompted subsequent studies to search for an alternative etiologic agent. Much of the early work was done with the hamster model, because clindamycin, as well as many other antibiotics, almost invariably caused a lethal cecitis that resembled the lesions found in patients. One of the first clues to a bacterial etiology in this model was the observation that clindamycin-induced disease could be prevented with oral vancomycin [5, 6]. The search for the alternative etiologic agent led to the detection of Clostridium difficile as the putative agent [7], and vancomycin was approved by the US Food and Drug Administration (FDA) for this indication; it quickly became standard therapy [8]. During the early 1980s, there were 3 important additional observations relevant to treatment: (1) the standard dose of vancomycin was reduced from 500 mg administered 4 times daily to 125 mg administered 4 times daily, (2) metronidazole appeared to be effective, and (3) both drugs were associated with relatively high rates of relapse after treatment was discontinued [8–12].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
Bartlett, J. G., Chang, T. W., Gurwith, M., Gorbach, S. L., & Onderdonk, A. B. (1978) · New England Journal of Medicine · doi:10.1056/nejm197803092981003 · Cited by 1,374 · cited 1×
“Clostridium difficile as the putative agent [7], and van-”
BackgroundSelf-citation
Cited by
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Cammarota, G., Masucci, L., Ianiro, G., Bibbò, S., Dinoi, G., Costamagna, G., Sanguinetti, M., & Gasbarrini, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13144 · Cited by 558
Carey-Ann, B. D., & Carroll, K. C. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-13 · Cited by 423
Clostridium difficile infection: epidemiology, risk factors and management
Ananthakrishnan, A. N. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.190 · Cited by 352
Metadata
- Authors
- Bartlett, J. G.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-05-15
- Volume
- 46
- Issue
- 10
- Pages
- 1489-1492
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2142802863
- Cited by
- 90
- References
- 1
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Case for Vancomycin as the Preferred Drug for Treatment of Clostridium difficile Infection. https://app.cochat.ai/papers/10.1086/587654
- The paper
- Bartlett, J. G. (2008). The Case for Vancomycin as the Preferred Drug for Treatment of Clostridium difficile Infection. Clinical Infectious Diseases. https://doi.org/10.1086/587654
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.